Eversept Partners, LP Celldex Therapeutics, Inc. Transaction History

Eversept Partners, LP

  • $904 Million
  • Q1 2025

A detailed history of Eversept Partners, LP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Eversept Partners, LP holds 696,499 shares of CLDX stock, worth $13.6 Million. This represents 1.4% of its overall portfolio holdings.

Number of Shares
696,499
Previous 719,836 3.24%
Holding current value
$13.6 Million
Previous $18.2 Million 30.51%
% of portfolio
1.4%
Previous 1.84%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025
SELL
$18.15 - $27.6 $423,566 - $644,101
-23,337 Reduced 3.24%
696,499 $12.6 Million
Q4 2024

Feb 14, 2025
BUY
$23.31 - $32.4 $3.61 Million - $5.02 Million
154,934 Added 27.43%
719,836 $18.2 Million
Q3 2024

Nov 14, 2024
SELL
$32.06 - $44.56 $2.18 Million - $3.04 Million
-68,113 Reduced 10.76%
564,902 $19.2 Million
Q2 2024

Aug 14, 2024
SELL
$32.76 - $42.56 $2.56 Million - $3.32 Million
-78,100 Reduced 10.98%
633,015 $23.4 Million
Q1 2024

May 15, 2024
SELL
$35.22 - $51.88 $1.51 Million - $2.23 Million
-42,992 Reduced 5.7%
711,115 $29.8 Million
Q4 2023

Feb 14, 2024
BUY
$22.61 - $40.65 $3.75 Million - $6.75 Million
165,964 Added 28.22%
754,107 $29.9 Million
Q3 2023

Nov 14, 2023
SELL
$25.45 - $37.46 $5.03 Million - $7.4 Million
-197,597 Reduced 25.15%
588,143 $16.2 Million
Q2 2023

Nov 08, 2023
BUY
$30.29 - $38.28 $2.91 Million - $3.68 Million
96,064 Added 13.93%
785,740 $26.7 Million
Q2 2023

Aug 14, 2023
BUY
$30.29 - $38.28 $2.91 Million - $3.68 Million
96,064 Added 13.93%
785,740 $26.7 Million
Q1 2023

Nov 08, 2023
BUY
$34.78 - $47.43 $4.55 Million - $6.21 Million
130,902 Added 23.43%
689,676 $24.8 Million
Q1 2023

May 15, 2023
BUY
$34.78 - $47.43 $4.55 Million - $6.21 Million
130,902 Added 23.43%
689,676 $24.8 Million
Q4 2022

Nov 08, 2023
SELL
$27.78 - $45.38 $1.88 Million - $3.07 Million
-67,598 Reduced 10.79%
558,774 $24.9 Million
Q4 2022

Feb 14, 2023
SELL
$27.78 - $45.38 $1.88 Million - $3.07 Million
-67,598 Reduced 10.79%
558,774 $24.9 Million
Q3 2022

Nov 08, 2023
BUY
$22.7 - $37.57 $1.68 Million - $2.78 Million
73,984 Added 13.39%
626,372 $17.6 Million
Q3 2022

Nov 14, 2022
BUY
$22.7 - $37.57 $1.68 Million - $2.78 Million
73,984 Added 13.39%
626,372 $17.6 Million
Q2 2022

Nov 08, 2023
SELL
$20.5 - $37.33 $1.72 Million - $3.14 Million
-84,065 Reduced 13.21%
552,388 $14.9 Million
Q2 2022

Aug 15, 2022
SELL
$20.5 - $37.33 $1.72 Million - $3.14 Million
-84,065 Reduced 13.21%
552,388 $14.9 Million
Q1 2022

Nov 08, 2023
SELL
$27.64 - $39.32 $4.13 Million - $5.87 Million
-149,287 Reduced 19.0%
636,453 $21.7 Million
Q1 2022

May 16, 2022
BUY
$27.64 - $39.32 $1.22 Million - $1.73 Million
43,975 Added 7.42%
636,453 $21.7 Million
Q4 2021

Nov 08, 2023
SELL
$35.68 - $56.27 $6.9 Million - $10.9 Million
-193,262 Reduced 24.6%
592,478 $22.9 Million
Q4 2021

Feb 14, 2022
BUY
$35.68 - $56.27 $21.1 Million - $33.3 Million
592,478 New
592,478 $22.9 Million
Q4 2020

Feb 16, 2021
SELL
$14.99 - $22.75 $2.26 Million - $3.42 Million
-150,494 Closed
0 $0
Q3 2020

Nov 08, 2023
SELL
$9.65 - $15.19 $5.43 Million - $8.54 Million
-562,204 Reduced 78.88%
150,494 $2.23 Million
Q3 2020

Nov 13, 2020
SELL
$9.65 - $15.19 $5.43 Million - $8.54 Million
-562,204 Reduced 78.88%
150,494 $2.23 Million
Q2 2020

Nov 08, 2023
SELL
$1.61 - $13.41 $117,597 - $979,493
-73,042 Reduced 9.3%
712,698 $9.27 Million
Q2 2020

Aug 13, 2020
BUY
$1.61 - $13.41 $1.15 Million - $9.56 Million
712,698 New
712,698 $9.27 Million

Others Institutions Holding CLDX

# of Institutions
188
Shares Held
69.3M
Call Options Held
220K
Put Options Held
310K
View Full List

About Celldex Therapeutics, Inc.

CLDX Quotes by TradingView
  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $913M
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Eversept Partners, LP Portfolio

Follow Eversept Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email